On Topic Virtual Roundtable: Optimizing Outcomes for Patients with Chronic Lymphocytic Leukemia in Community Practice
Release Date: June 30, 2022
Expiration Date: June 29, 2023
On Topic Virtual RoundtableTM : Optimizing Outcomes for Patients with Chronic Lymphocytic Leukemia in Community Practice aims to focus on providing community-based clinicians with clinical recommendations to address treatment options for patients with CLL.
This target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.
After participating in this activity, learners should be better able to:
- Review how patient- and disease-related factors such as age, performance status, comorbidities, and mutational status impact the choice of therapy for patients with CLL
- Evaluate recent clinical trial data focused on current and emerging treatment options for patients with newly diagnosed and relapsed/refractory CLL
- Determine the optimal approach to the sequencing of targeted therapies and small molecule inhibitors, as well as emerging combinations of agents for patients with relapsed/refractory CLL
- Develop strategies to optimize patient-related outcomes, including mitigating treatment-related adverse events, improving the quality of life, and recognizing the role of the patient voice in selecting therapeutic approaches
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
Matthew Davids, MD, MMSc (Moderator)
Director, Clinical Research, Division of Lymphoma
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.
Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.
Jeffrey Bubis, DO, FACOI, FACP
Florida Cancer Specialists and Research Center
Fleming Island, Florida
Advisor: Blueprint Medicines, Pharmacosmos, Puma Biotechnology
Divis Khaira, MD
No relevant financial relationships to disclose
15 year CLL Survivor and Patient Advocate
No relevant financial relationships to disclose
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Tisheeka Graham-Steed, PhD; Kraig Steubing
This activity is supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.